How has been the historical performance of Strides Pharma?

Answer:The historical performance of Strides Pharma shows significant fluctuations and trends over the years, culminating in a notable recovery in the latest fiscal year.

Breakdown:
Strides Pharma's net sales have steadily increased from 2,178.37 Cr in March 2019 to 4,565.34 Cr in March 2025, indicating a strong growth trajectory. Total operating income followed a similar trend, rising from 2,178.37 Cr to 4,565.34 Cr over the same period. However, the company faced challenges with raw material costs, which increased from 1,002.05 Cr in March 2019 to 1,475.89 Cr in March 2025, alongside a rise in employee costs from 329.44 Cr to 862.76 Cr. Operating profit (PBDIT) saw a significant recovery, moving from a loss of 20.11 Cr in March 2022 to a profit of 802.82 Cr in March 2025. Profit before tax also improved dramatically, from a loss of 541.70 Cr in March 2022 to a profit of 485.08 Cr in March 2025. The net profit turned from a loss of 363.44 Cr in March 2022 to a substantial profit of 3,593.46 Cr in March 2025. The company's total assets decreased from 6,760.71 Cr in March 2022 to 5,779.59 Cr in March 2025, while total liabilities also decreased from 6,760.71 Cr to 5,779.59 Cr during the same period. Cash flow from operating activities improved significantly, reaching 684.00 Cr in March 2025, compared to a negative cash flow of 257.00 Cr in March 2022. Overall, Strides Pharma's financial performance reflects a recovery and growth phase, particularly in profitability and operational efficiency.